APOE and metabolic dysfunction-associated steatotic liver disease: Furthermore, an ApoE/miR-155 double KO mouse model provided significant insights into the complex interplay among obesity, atherosclerosis, and non-alcoholic fatty liver disease (NAFLD), where, despite increased adipogenesis, these mice showed a reduction in atherosclerotic lesions [116].